Press Releases Mar 01 2024 Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories Read More Feb 16 2024 Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share Read More Nov 09 2023 Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates Read More View All Upcoming Events Investor Relations events will be posted soon. View All
Mar 01 2024 Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories Read More
Feb 16 2024 Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share Read More
Nov 09 2023 Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates Read More
